Published in
Elsevier, The Lancet Oncology, 5(19), p. 682-693, 2018
DOI: 10.1016/s1470-2045(18)30146-3
Links
Tools
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Journal article published in 2018 by
Lorenza Rimassa 
,
Eric Assenat,
Markus Peck-Radosavljevic,
Marc Pracht,
Vittorina Zagonel,
Philippe Mathurin,
Elena Rota Caremoli,
Camillo Porta,
Bruno Daniele,
Luigi Bolondi,
Vincenzo Mazzaferro,
William Harris,
Nevena Damjanov,
Davide Pastorelli,
María Reig
and other authors.
,
Eric Assenat,
Markus Peck-Radosavljevic,
Marc Pracht,
Vittorina Zagonel,
Philippe Mathurin,
Elena Rota Caremoli,
Camillo Porta,
Bruno Daniele,
Luigi Bolondi,
Vincenzo Mazzaferro,
William Harris,
Nevena Damjanov,
Davide Pastorelli,
María Reig
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 